王坤. 帕妥珠单抗联合曲妥珠单抗和多西紫杉醇一线治疗转移性乳腺癌提高患者的总生存期[J]. 循证医学, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
    引用本文: 王坤. 帕妥珠单抗联合曲妥珠单抗和多西紫杉醇一线治疗转移性乳腺癌提高患者的总生存期[J]. 循证医学, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
    WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002
    Citation: WANG Kun. Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(2): 66-66. DOI: 10.3969/j.issn.1671-5144.2015.02.002

    帕妥珠单抗联合曲妥珠单抗和多西紫杉醇一线治疗转移性乳腺癌提高患者的总生存期

    Pertuzumab, Trastuzumab, and Docetaxel as First-Line Treatment to Improve the Overall Survival of Patients with Metastatic Breast Cancer

    • 摘要: 编者按: 为了帮助临床医生鉴别、评价和应用当前临床实践中的最佳证据,我刊新创“热点评论”栏目。选取国际知名杂志发表的最新、重要的随机对照研究,真实世界大样本研究,关注未来发展方向的文献(临床研究或转化研究),以及中国学者在国外杂志上发表的重要文献,就研究设计的合理性、结论的可靠性、尚存在的不足、我们在临床实践中应用这些结论时应注意的问题进行深度评论。敬请相关学科的医务工作者关注。

       

    /

    返回文章
    返回